|
Volumn 353, Issue 25, 2005, Pages 2637-2639
|
Safety of long-acting beta-agonists - An urgent need to clear the air
|
Author keywords
[No Author keywords available]
|
Indexed keywords
BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT;
BETA ADRENERGIC RECEPTOR STIMULATING AGENT;
BRONCHODILATING AGENT;
CORTICOSTEROID;
FLUTICASONE;
FLUTICASONE PROPIONATE PLUS SALMETEROL;
FORMOTEROL;
FORMOTEROL FUMARATE;
LEUKOTRIENE RECEPTOR BLOCKING AGENT;
SALBUTAMOL;
SALMETEROL;
THEOPHYLLINE;
AIR;
ASTHMA;
CLINICAL TRIAL;
DEATH;
DRUG EFFICACY;
FOOD AND DRUG ADMINISTRATION;
HEALTH PRACTITIONER;
HOSPITALIZATION;
HUMAN;
MONITORING;
MORTALITY;
PRIORITY JOURNAL;
PUBLIC HEALTH;
RISK ASSESSMENT;
SAFETY;
SHORT SURVEY;
ADRENAL CORTEX HORMONES;
ADRENERGIC BETA-AGONISTS;
ALBUTEROL;
ASTHMA;
CLINICAL TRIALS;
DRUG THERAPY, COMBINATION;
ETHANOLAMINES;
GREAT BRITAIN;
HUMANS;
UNITED STATES;
|
EID: 29144531153
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMp058299 Document Type: Short Survey |
Times cited : (150)
|
References (5)
|